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Abstract
Background: Caveolin-1 is a scaffolding protein found in plasma membrane invaginations known as caveolae.
Caveolin-1 can regulate a number of intracellular processes such as signal transduction, cholesterol metabolism
and vesicular transport. With respect to breast cancer caveolin-1 has been observed in both tumor cells and
stromal cells surrounding tumors however most of the recent research has focused on how the loss of caveolin-1
in the stromal cells surrounding the tumor alters the tumor microenvironment.
Methods: Caveolin-1 expression was evaluated in (1) mammary tumors induced by the transgenic overexpression
of the type I insulin-like growth factor receptor (IGF-IR), (2) mammary tumors that became independent of IGF-IR
signalling and acquired a claudin-low genotype, (3) two murine mammary epithelial tumor cell lines and (4) two
murine mammary claudin-low tumor cell lines.
Results: We found that mammary tumors induced by IGF-IR overexpression expressed low levels of caveolin-1
while mammary tumors that became independent of IGF-IR signalling expressed considerably higher levels of
caveolin-1. Interestingly, pockets of caveolin-1 positive cells could be observed in some of the IGF-IR-induced
mammary tumors and these caveolin-1 positive cells were associated with tumor cells that expressed basal
cytokeratins (cytokeratins 5 and 14). This caveolin-1 expression pattern was maintained in the murine mammary
tumor cell lines in that the epithelial mammary tumor cell lines expressed little or no caveolin-1 while the claudin-
low cell lines expressed caveolin-1.
Conclusions: Our model indicates that mammary tumor cells with epithelial characteristics lack caveolin-1 while
mesenchymal tumor cells express caveolin-1 suggesting that caveolin-1 may serve as a marker of mammary tumor
cells with mesenchymal characteristics such as claudin-low breast tumors.
Background
Caveolin-1 (Cav-1) is a member of the caveolin family
which consists of Cav-1, Cav-2 and Cav-3. Caveolins
function as scaffolding proteins and are found in plasma
membrane invaginations known as caveolae. Cav-1 and
Cav-2 are co-expressed and found in a number of cell
types including endothelial cells, adipocytes, and type I
alveolar cells while Cav-3 is expressed in skeletal, car-
diac and smooth muscle cells [1-4]. In normal cells
caveolins regulate signal transduction, cholesterol meta-
bolism, and vesicular transport.
Most of the work performed on Cav-1 in breast can-
cer has been directed towards the stromal cells. Loss of
Cav-1 in stromal cells surrounding breast cancers has
been associated with disease recurrence, metastasis,
tamoxifen resistance and poor clinical outcome [5,6]. It
has been suggested that loss of Cav-1 in tumor-asso-
ciated fibroblasts induces aerobic glycolysis in these cells
resulting in increased production of pyruvate and lac-
tate. The adjacent tumor cells would then utilize these
substrates for ATP production. This phenomenon has
been termed “Reverse Warburg Effect” [7-10]. A modifi-
cation of this hypothesis suggests that loss of stroma
Cav-1 increases autophagy in the tumor microenviron-
ment leading to recycled nutrients that can be utilized
by the tumor cells and protection of the tumor cells
from apoptosis and autophagy [11-14].
There have been some studies investigating Cav-1
levels in breast tumor cells. In two independent studies
Cav-1 expression was found to be lower in human
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[15,16]. In addition, overexpression of Cav-1 in human
breast cancer cell lines inhibited proliferation and soft
agar colony formation [16]. However, studies by Heiser
et al. [17] and Elsheikh et al. [18] showed that Cav-1
was frequently observed in basal but not luminal, breast
cancer cells. Therefore, Cav-1 may be expressed only in
certain breast cancer subtypes.
Cav-1 null mice have been created and display mam-
mary epithelial hyperplasia [19-21]. Since Cav-1 expres-
sion is lost in all cells in these mice it is difficult to
determine whether the hyperplasia results from Cav-1
loss in the epithelial cells, stromal cells or both. To
examine the effects of Cav-1 loss directly on mammary
epithelial cells, mammary epithelial cells from Cav-1
null mice were transplanted into the mammary fat pad
of wild type mice. Cav-1 deficient mammary epithelial
cells displayed increases in proliferation, terminal end
bud area, and mammary ductal thickness [21].
Our group became interested in Cav-1 following the
analysis of DNA microarray results that compared mam-
m a r yt i s s u ef r o mw i l dt y p em i c et ot u m o rt i s s u ef r o m
transgenic mice that express elevated levels of the type I
insulin-like growth factor receptor (IGF-IR) in mammary
epithelial cells. Cav-1 was significantly downregulated
(~37-fold) in the mammary tumor tissue compared to
normal mammary tissue [22]. Interestingly, tumors that
recurred following IGF-IR downregulation in the mam-
mary tumors acquired a claudin-low phenotype and gen-
otype and expressed Cav-1 at significantly higher levels
(~14-fold) than the initial mammary tumor [22]. To
study these differences further, Cav-1 expression was
evaluated in mammary tumor tissue and mammary
tumor cell lines. We found that the differences in Cav-1
expression were a result of tumor cell Cav-1 rather than
stromal Cav-1. Epithelial mammary tumors expressed
low levels of Cav-1 while claudin-low mammary tumors
expressed much higher levels of Cav-1. These findings
were confirmed in two murine mammary epithelial
tumor cell lines and two murine mammary claudin-low
cell lines in that the claudin-low cell lines expressed ele-
vated levels of Cav-1 compared to the epithelial ones.
Therefore, our findings suggest that Cav-1 expression
can be used to differentiate mammary tumors with
epithelial characteristic from those with mesenchymal or
more specifically, claudin-low characteristics.
Methods
MTB-IGFIR transgenic mice
The initial generation and characterization of transgenic
mice overexpressing the type I insulin-like growth
receptor (IGF-IR) has been presented in [23]. Genera-
tion of tumors following downregulation of the IGF-IR
transgene has been described in [24]. Animals were
housed and cared for following guidelines established by
the Central Animal Facility at the University of Guelph
and the guidelines established by the Canadian Council
of Animal Care.
Cell lines and culture conditions
4T1 cells were obtained from the ATCC (Manassas, VA)
and were cultured in DMEM media containing 10% FBS,
1 mM sodium pyruvate, 10 mM Hepes and 4 mM L-gluta-
mine. RM11A, RJ345 and RJ348 cells were created from
different tumors of MTB-IGFIR transgenic mice and they
are described in [25]. RM11A, RJ345 and RJ348 cells were
cultured in media described in [26] with RM11A and
RJ345 being cultured in media supplemented with 10 μg/
mL doxycycline for transgene induction while RJ348 cells
were cultured in doxycycline-free media.
Western blotting
Western blotting was performed as previously described
[23]. Caveolin-1 antibody was obtained from BD Bios-
ciences (Mississauga, ON, Canada) and used at a
1:20,000 dilution while the b-actin antibody was pur-
chased from Sigma (St Louis, MO) and used at a
1:2,000 dilution. Secondary antibodies were purchased
from Cell Signaling Technology (Danvers, MA) and
used at a 1:2,000 dilution. Bands were visualized using a
FluorChem9900 imaging system and AlphaEaseFC soft-
ware (Alpha Innotech, San Leandro, CA).
Immunohistochemistry
Immunohistochemistry was performed as previously
described [23]. Caveolin-1 antibody (BD Biosciences,
Mississauga, ON, Canada) was used at a 1:10,000 dilu-
tion while cytokeratin 5 and cytokeratin 14 antibodies
were purchased from Abcam (Cambridge, MA) and
used at a 1:100 dilution. Primary antibodies were
detected with the appropriate secondary antibody
(Sigma, St Louis, MO) used at a 1:200 dilution and
Sigma Fast 3,3’-diaminobenzidine tablets (Sigma, St
Louis, MO).
Immunofluorescence
Immunofluorescence was performed as previously
described [26]. Caveolin-1 antibody (BD Biosciences,
Mississauga, ON, Canada) was used at a dilution of
1:10,000. Cell nuclei were counterstained with DAPI.
Images were captured on an Olympus BX61 fluorescent
microscope (Olympus, Center Valley, PA) using Meta-
morph imaging software (Molecular Devices, Sunnyvale,
CA).
Quantitative real-time PCR
Total RNA was extracted from cells cultured to approxi-
mately 75% confluency, 2 d after plating using the
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systems, Streetsville, ON), in accordance with the manu-
facturer’s instructions (without the miRNA enrichment
step). Real time PCR was performed as described in
[24]. All primers were obtained from Origene (Rockville,
MD).
Statistics
Statistical significance was determined using an ANOVA
followed by a Tukey’s HSD post-hoc test. Values were
considered statistically significant when p < 0.05.
Results
DNA microarray analysis was used to compare three
sets of murine tissues; (i) adult, wild type mammary tis-
sue (WT), (ii) primary mammary tumors induced by
transgenic IGF-IR overexpression which present with an
epithelial morphology (PMT; primary mammary tumor),
and (iii) mammary tumors that resume growth following
IGF-IR downregulation. These tumors that arise follow-
ing IGF-IR downregulation express low levels of the
IGF-IR and present with a spindle shaped morphology
(RST; recurrent spindle tumor). The partial characteriza-
tion of these tumors has been presented in [24] while
characterization of the IGF-IR transgenic mice (MTB-
IGFIR mice) has been presented in [23].
The DNA microarray analysis indicated that Cav-1
was reduced approximately 37-fold in the PMT tissue
compared to WT mammary tissue [22]. As Cav1 is
expressed in adipocytes, endothelial cells, myoepithelial
cells and fibroblasts but not epithelial cells [1-4] this
finding was not completely surprising as the PMTs are
composed primarily of epithelial cells [23]. Interestingly,
Cav-1 expression was somewhat restored in the RST tis-
sue. Cav-1 expression as determined by the DNA micro-
array was approximately 14-fold higher in the RST
samples compared to the PMT samples [22]. To confirm
the DNA microarray findings, western blotting was per-
formed and these blots showed that the levels of Cav-1
protein were highest in normal mammary tissue from
WT mice, reduced in the PMTs and somewhat restored
in the RSTs (Figure 1).
To determine whether Cav-1 was being expressed in
the tumor cells and/or the stromal cells, immunohisto-
chemistry for Cav-1 was performed. In the PMT tissue
sections adipocytes and cells lining blood vessels stained
strongly for Cav-1 protein as did basal cells in normal
mammary ducts (Figure 2A; arrow). The tumor cells
themselves primarily expressed only low levels of Cav-1
protein (Figure 2A; T) however some regions of the
PMT had clusters of cells that stained positive for Cav-1
(Figure 2B, arrowhead). Therefore, most of the tumor
cells in PMTs express low levels of Cav-1 however,
pockets of tumor cells expressing high levels of Cav-1
can be found within some of these tumors. PMTs in the
MTB-IGFIR transgenic mice are not typically sur-
rounded by fibroblasts. In a few tumors where fibro-
blasts could be found adjacent to the mammary tumor,
these fibroblasts displayed little or no staining for Cav-1
(Figure 2A, B). In the RST tissue sections, Cav-1 protein
could be detected at moderate (Figure 2C) or high
(Figure 2D) levels in the tumor cells themselves. The
level of Cav-1 staining was variable between different
RSTs and within individual RSTs. Fibroblasts associated
with RSTs could not be readily detected and thus the
level of Cav-1 in RST associated fibroblasts could not be
determined. The levels of Cav-1 were also examined in
lung metastases that developed in the MTB-IGFIR
transgenic mice. Approximately 30% of MTB-IGFIR
transgenic mice develop lung metastases. In general, the
lung metastases expressed very low levels of Cav-1 com-
pared to the surround lung tissue (Figure 2E). One
mouse had a number of large lung metastases and these
metastases had pockets of Cav-1 positive cells (Figure
2F, arrowhead).
The pockets of Cav-1 positive cells observed in the
PMT samples appeared to be associated with regions
that had undergone some squamous differentiation.
These regions were reported previously [23] and were
shown to contain cells expressing cytokeratins 5 and 14.
To determine whether Cav-1 positive cells also
expressed cytokeratin 5 and 14, immunohistochemistry
for Cav-1, cytokeratin 5 and cytokeratin 14 was per-
formed on serial sections of two distinct mammary
tumors. Although Cav-1 failed to completely co-localize
with either cytokeratin 5 or cytokeratin 14, most of the
Cav-1 positive cells were found in regions of the tumor
were there was an abundance of cytokeratin 5 or cyto-
keratin 14 positive cells (Figure 3). Little or no Cav-1
was observed in regions of the tumor where the cells
were negative for either cytokeratin 5 or 14. This sug-
g e s t st h a tC a v - 1i se x p r e s s e da tl o wl e v e l si nt u m o r
epithelial cells but at higher levels in regions associated
with basal/mesenchymal tumor cells.
Figure 1 Western blot of Cav-1 protein in 4 independent wild
type (WT) mammary tissue sample, 4 independent primary
mammary tumor (PMT) tissue samples induced by transgenic
overexpression of IGF-IR, and 4 independent recurrent spindle
tumor (RST) tissue samples which developed after the
downregulation of the IGF-IR transgene. b-actin served as a
loading control
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and RST tumors of the MTB-IGFIR transgenic mice.
These lines have recently been characterized [25]. Two
of the cell lines (RM11A and RJ348) have characteristics
of claudin-low mammary tumors while a cell line, RJ345
has characteristics similar to luminal tumors [25]. 4T1
Figure 2 Cav-1 immunohistochemistry in PMT tissue (A, B), RST tissue (C, D) and two different lung metastases (E, F). The arrows in (A)
indicate Cav-1 positive cells lining blood vessels in normal mammary tissue while T marks the mammary tumor. The arrowhead in (B) highlights
Cav-1 positive tumor cells within a PMT sample. In panels (E, F) LM identifies the lung metastasis while NL identifies normal lung tissue. Scale
bars, 100 μm
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epithelial cell line [27] that has previously been shown
to have characteristics similar to the RJ345 cells [25].
Western blotting and immunofluorescence for Cav-1
protein and qRT-PCR for Cav-1 mRNA revealed that
tumor cells themselves can express Cav-1 and the clau-
din-low mammary tumor cell lines (RJ348 and RM11A)
expressed higher levels of Cav-1 protein and mRNA
than the epithelial tumor cell lines (Figure 4 and
Table 1).
Discussion
Most of the current research on Cav-1 in breast cancer
has demonstrated that loss of Cav-1 expression in the
stromal cells surrounding the tumor is associated with
early tumor recurrence and poor clinical outcome [5,6].
It has been proposed that loss of stromal Cav-1 induces
oxidative stress within the fibroblasts which in turn
results in an increased secretion of lactate and pyruvate
by the stromal fibroblast and/or autophagy in the stro-
mal compartment [13,14,28]. In both instances, the stro-
mal cells provide essential fuel for tumor growth. Loss
of stromal Cav-1 has also been associated with epithelial
to mesenchymal transition (EMT) of mammary epithe-
lial cells. It was shown that conditioned media from
Cav-1 null mammary stromal fibroblasts could induce
EMT of normal mammary epithelial cells [29]. EMT is a
program where epithelial tumor cells acquire genetic
and phenotypic characteristics of mesenchymal cells and
these cells show enhanced invasive capacity and poten-
tially stem cell characteristics [30,31].
However, Cav-1 may also directly affect tumor cells as
transformation of NIH-3T3 cells with oncogenes such
as H-Ras is associated with decreased Cav-1 expression
and re-expression of Cav-1 can inhibit anchorage-inde-
pendent growth of transformed NIH-3T3 cells. This
finding, coupled with our observation that Cav-1 was
significantly elevated in our DNA microarray comparing
claudin-low mammary tumors to our primary, IGF-IR
induced epithelial mammary tumors led us to examine
the expression of Cav-1 in the tumor cells themselves.
Claudin-low breast cancers are a subtype of human
breast cancer characterized by low levels of epithelial
genes and high levels of mesenchymal genes as well as
genes involved in the immune response and those asso-
ciated with stem cells [32,33].
In our MTB-IGFIR transgenic model [23,24], Cav-1
was found to be expressed in adipocytes and smooth
muscle cells in the mammary gland but the cells of
mammary tumors induced by IGF-IR overexpression
expressed considerably less Cav-1. Most of the epithelial
cells of the mammary tumors expressed little or no
Cav-1 protein. However, there were small pockets of
cells within some of the IGF-IR induced mammary
tumors. Interestingly, these pockets of Cav-1 cells were
in close proximity to cells within the tumor expressing
Figure 3 Immunohistochemistry for Cav-1 (A, D), cytokeratin 5 (B, E), and cytokeratin 14 (C, F) on serial sections from two different
PMT samples. Scale bars, 100 μm
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frequently were associated with ghost cells. In contrast,
mammary tumors that develop following IGF-IR down-
regulation and acquire a claudin-low genotype express
moderate to high levels of Cav-1 in the tumor cells
themselves. This pattern of Cav-1 expression was main-
tained in mammary tumor cell lines derived from MTB-
IGFIR transgenic tumors with epithelial or claudin-low
characteristics. Therefore, Cav-1 levels were higher in
claudin-low tumor cells than epithelial tumor cells.
Figure 4 (A) Western blot of Cav-1 protein in two epithelial murine mammary tumor cell lines (4T1 and RJ345) and two murine
mammary claudin-low cell lines (RJ348 and RM11A). b-actin served as a loading control. Immunofluorescence of Cav-1 (green) in RJ345 (B),
4T1 (C), RJ348 (D) and RM11A (E). Blue fluorescence indicates cell nuclei staining positive for DAPI; scale bars, 50 μm
Table 1 Cav-1 mRNA Levels
Cell Line Cav-1 mRNA
4T1 0.12 ± 0.02
1
RJ345 0.37 ± 0.08
RJ348 1.81 ± 0.06
a
RM11A 1.06 ± 0.20
a
1Values represent mean ± SEM and are Expressed Relative to HPRT mRNA
aSignificantly higher than 4T1 or RJ345
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ports the findings of Bailey and Liu [34] who observed
that induction of EMT in embryonic carcinoma cells or
murine mammary epithelial cells was associated with
elevated Cav-1 expression. In addition, Orlichenko et al.
observed that decreased Cav-1 expression or function
resulted in elevated E-cadherin levels in MDCK epithe-
lial cells [35]. Moreover, Savage et al. [36] found that
Cav-1 was expressed at high levels in basal-like and
metaplastic breast tumors while Prat et al. [33] and Haa-
kensen et al. [37] have observed higher levels of Cav-1
in human claudin-low breast tumors or cell lines.
These findings are all consistent with our findings
since we found that IGF-IR-induced mammary tumors
and murine mammary tumor cell lines 4T1 and RJ345
that expressed high levels of E-cadherin and low levels
of mesenchymal genes also expressed low levels of Cav-
1. In contrast, IGF-IR independent mammary tumors
and the murine mammary tumor cell lines RJ348 and
RM11A that expressed very low levels of E-cadherin and
had gene expression patterns similar to claudin-low
tumors also expressed considerable amounts of Cav-1.
Therefore, our study supports the findings that claudin-
low mammary tumors express more Cav-1 than epithe-
lial mammary tumors. Cav-1 may be useful with other
markers in identifying/distinguishing claudin-low human
breast tumors.
In general, lung metastases expressed low levels of
Cav-1 protein while normal lung alveolar cells expressed
much higher levels of Cav-1. The alveolar expression of
Cav-1 was not unexpected as Cav-1 has been reported
to be expressed in type I pneumocytes [38]. This finding
suggests that Cav-1 is not important in growth of
tumors at secondary sites. Although we have not exten-
sively characterized the lung metastases these lesions do
appear to have an epithelial morphology and thus if the
tumor cells in the metastases are primarily epithelial we
would not expect them to express high levels of Cav-1.
A search of the literature did not reveal any papers
describing the expression of Cav-1 in breast metastatic
lesions.
Our findings suggest that Cav-1 expression is depen-
dent of the subtype of mammary tumor being investi-
gated. It appears that epithelial mammary tumors
express low levels of Cav-1 but mammary tumors that
acquire claudin-low characteristics express Cav-1.
Further investigations are required to determine whether
Cav-1 can be used as a marker and/or a therapeutic tar-
get for claudin-low breast cancers.
Authors’ contributions
DET performed the western blot, immunofluorescence and RT-PCR for Cav1
while MDS sectioned all of the tissue, performed the histology and
immunohistochemistry. RAM ran the project and wrote the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 December 2011 Accepted: 22 February 2012
Published: 22 February 2012
References
1. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP:
Identification, sequence, and expression of caveolin-2 defines a caveolin
gene family. Proc Natl Acad Sci USA 1996, 93:131-135.
2. Kurzchalia TV, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, et al:
VIP21, a 21-kD membrane protein is an integral component of trans-
Golgi-network-derived transport vesicles. J Cell Biol 1992, 118:1003-1014.
3. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, et al: Molecular
cloning of caveolin-3, a novel member of the caveolin gene family
expressed predominantly in muscle. J Biol Chem 1996, 271:2255-2261.
4. Way M, Parton RG: M-caveolin, a muscle-specific caveolin-related protein.
FEBS Lett 1995, 376:108-112.
5. Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G,
et al: Towards a new “stromal-based” classification system for human
breast cancer prognosis and therapy. Cell Cycle 2009, 8:1654-1658.
6. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al: An
absence of stromal caveolin-1 expression predicts early tumor
recurrence and poor clinical outcome in human breast cancers. Am J
Pathol 2009, 174:2023-2034.
7. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S,
Pestell RG, et al: Glycolytic cancer associated fibroblasts promote breast
cancer tumor growth, without a measurable increase in angiogenesis:
Evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010,
9:2412-2422.
8. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al:
Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and
drives inflammation in the tumor microenvironment, conferring the
“reverse Warburg effect": A transcriptional informatics analysis with
validation. Cell Cycle 2010, 9:2201-2219.
9. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG,
Fatatis A, et al: The reverse Warburg effect: glycolysis inhibitors prevent
the tumor promoting effects of caveolin-1 deficient cancer associated
fibroblasts. Cell Cycle 2010, 9:1960-1971.
10. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N,
Witkiewicz AK, Frank PG, et al: The reverse Warburg effect: aerobic
glycolysis in cancer associated fibroblasts and the tumor stroma. Cell
Cycle 2009, 8:3984-4001.
11. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B,
Pavlides S, Wang C, et al: Oxidative stress in cancer associated fibroblasts
drives tumor-stroma co-evolution: A new paradigm for understanding
tumor metabolism, the field effect and genomic instability in cancer
cells. Cell Cycle 2010, 9:3256-3276.
12. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D,
Chiavarina B, Zhou J, et al: Autophagy in cancer associated fibroblasts
promotes tumor cell survival: Role of hypoxia, HIF1 induction and
NFkappaB activation in the tumor stromal microenvironment. Cell Cycle
2010, 9:3515-3533.
13. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B,
Flomenberg N, et al: The autophagic tumor stroma model of cancer: Role
of oxidative stress and ketone production in fueling tumor cell
metabolism. Cell Cycle 2010, 9:3485-3505.
14. Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-
Outschoorn UE, et al: Caveolin-1 and mitochondrial SOD2 (MnSOD)
function as tumor suppressors in the stromal microenvironment: a new
genetically tractable model for human cancer associated fibroblasts.
Cancer Biol Ther 2011, 11:383-394.
15. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, et al:
RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb
Symp Quant Biol 1994, 59:537-546.
16. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE: Tumor cell growth
inhibition by caveolin re-expression in human breast cancer cells.
Oncogene 1998, 16:1391-1397.
Thompson et al. Cancer Cell International 2012, 12:6
http://www.cancerci.com/content/12/1/6
Page 7 of 817. Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, et al:
Integrated analysis of breast cancer cell lines reveals unique signaling
pathways. Genome Biol 2009, 10:R31.
18. Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D, et al:
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like
and triple-negative immunophenotype. Br J Cancer 2008, 99:327-334.
19. Razani B, Lisanti MP: Caveolin-deficient mice: insights into caveolar
function human disease. J Clin Invest 2001, 108:1553-1561.
20. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, et al: Mice
with cav-1 gene disruption have benign stromal lesions and
compromised epithelial differentiation. Exp Mol Pathol 2008, 84:131-140.
21. Williams TM, Sotgia F, Lee H, Hassan G, Di VD, Bonuccelli G, et al: Stromal
and epithelial caveolin-1 both confer a protective effect against
mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin
D1 function in mammary epithelial cells. Am J Pathol 2006,
169:1784-1801.
22. Franks SE, Campbell CI, Barnett EF, Siwicky MD, Livingstone J, Cory S, et al:
Transgenic IGF-IR overexpression induces mammary tumors with basal-
like characteristics while IGF-IR independent mammary tumors express a
claudin-low gene signature. Oncogene 2011.
23. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al:
Transgenic overexpression of IGF-IR disrupts mammary ductal
morphogenesis and induces tumor formation. Oncogene 2007,
26:1636-1644.
24. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA: Reversibility
and recurrence of IGF-IR-induced mammary tumors. Oncogene 2008,
13:407-413.
25. Campbell CI, Thompson DE, Siwicky MD, Moorehead RA: Murine mammary
tumor cells with a claudin-low genotype. Cancer Cell Int 2011, 11:28.
26. Jones RA, Campbell CI, Petrik JJ, Moorehead RA: Characterization of a
novel primary mammary tumor cell line reveals that cyclin D1 is
regulated by the type I insulin-like growth factor receptor. Mol Cancer
Res 2008, 6:819-828.
27. Aslakson CJ, Miller FR: Selective events in the metastatic process defined
by analysis of the sequential dissemination of subpopulations of a
mouse mammary tumor. Cancer Res 1992, 52:1399-1405.
28. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE,
Pavlides S, Howell A, et al: HIF1-alpha functions as a tumor promoter in
cancer associated fibroblasts, and as a tumor suppressor in breast
cancer cells: Autophagy drives compartment-specific oncogenesis. Cell
Cycle 2010, 9:3534-3551.
29. Sotgia F, Del GF, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D,
et al: Caveolin-1-/- null mammary stromal fibroblasts share
characteristics with human breast cancer-associated fibroblasts. Am J
Pathol 2009, 174:746-761.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al: The
epithelial-mesenchymal transition generates cells with properties of
stem cells. Cell 2008, 133:704-715.
31. Hollier BG, Evans K, Mani SA: The epithelial-to-mesenchymal transition
and cancer stem cells: a coalition against cancer therapies. J Mammary
Gland Biol Neoplasia 2009, 14:29-43.
32. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al:
Identification of conserved gene expression features between murine
mammary carcinoma models and human breast tumors. Genome Biol
2007, 8:R76.
33. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al:
Phenotypic and molecular characterization of the claudin-low intrinsic
subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
34. Bailey KM, Liu J: Caveolin-1 up-regulation during epithelial to
mesenchymal transition is mediated by focal adhesion kinase. J Biol
Chem 2008, 283:13714-13724.
35. Orlichenko L, Weller SG, Cao H, Krueger EW, Awoniyi M, Beznoussenko G,
et al: Caveolae mediate growth factor-induced disassembly of adherens
junctions to support tumor cell dissociation. Mol Biol Cell 2009,
20:4140-4152.
36. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, et al:
Caveolin 1 is overexpressed and amplified in a subset of basal-like and
metaplastic breast carcinomas: a morphologic, ultrastructural,
immunohistochemical, and in situ hybridization analysis. Clin Cancer Res
2007, 13:90-101.
37. Haakensen VD, Lingjaerde OC, Luders T, Riis M, Prat A, Troester MA, et al:
Gene expression profiles of breast biopsies from healthy women
identify a group with claudin-low features. BMC Med Genomics 2011, 4:77.
38. Glenney JR Jr: Soppet D: Sequence and expression of caveolin, a protein
component of caveolae plasma membrane domains phosphorylated on
tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci
USA 1992, 89:10517-10521.
doi:10.1186/1475-2867-12-6
Cite this article as: Thompson et al.: Caveolin-1 expression is elevated in
claudin-low mammary tumor cellsP. Cancer Cell International 2012 12:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thompson et al. Cancer Cell International 2012, 12:6
http://www.cancerci.com/content/12/1/6
Page 8 of 8